Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) have been given an average recommendation of “Buy” by the seven research firms that are currently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $20.42.
Several equities analysts have commented on ALXO shares. Piper Sandler upped their price target on ALX Oncology from $8.00 to $11.00 and gave the company an “overweight” rating in a report on Wednesday, October 11th. UBS Group dropped their target price on ALX Oncology from $29.00 to $27.00 and set a “buy” rating for the company in a report on Wednesday, October 4th. Stifel Nicolaus dropped their target price on ALX Oncology from $11.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, November 14th. Cantor Fitzgerald increased their target price on ALX Oncology from $18.00 to $23.00 and gave the stock an “overweight” rating in a report on Wednesday, October 4th. Finally, HC Wainwright increased their target price on ALX Oncology from $16.00 to $17.50 and gave the stock a “buy” rating in a report on Tuesday, October 3rd.
Institutional Trading of ALX Oncology
ALX Oncology Price Performance
NASDAQ ALXO opened at $9.50 on Friday. The stock has a 50-day simple moving average of $7.04 and a 200 day simple moving average of $6.62. The company has a debt-to-equity ratio of 0.06, a quick ratio of 12.49 and a current ratio of 5.66. The stock has a market capitalization of $473.29 million, a PE ratio of -2.66 and a beta of 1.41. ALX Oncology has a twelve month low of $3.94 and a twelve month high of $12.33.
ALX Oncology Company Profile
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer.
- Five stocks we like better than ALX Oncology
- What Are Defense Contractor Stocks? How to Invest in Defense
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- How to Invest in Semiconductors
- MarketBeat Week in Review – 11/13 – 11/17
- Retail Stocks Investing, Explained
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.